Boston Scientific Corporation (NYSE:BSX) surged 4.08% in premarket trading on Wednesday after the medical device maker delivered third-quarter results that comfortably topped Wall Street expectations, fueled by broad-based strength across its business segments.
The company reported adjusted earnings per share of $0.75, beating the analyst consensus of $0.71. Revenue rose to $5.07 billion, ahead of forecasts of $4.97 billion, marking a 20.3% increase from the same period last year. Organic revenue growth came in at 15.3%, surpassing the firm’s prior guidance of 12% to 14%.
“We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team,” said Mike Mahoney, chairman and chief executive officer of Boston Scientific.
The Cardiovascular segment was the primary growth driver, with revenue climbing 22.4%, while MedSurg sales grew 16.4%. U.S. revenue jumped 27% year-over-year, reflecting particularly strong domestic momentum.
Following the upbeat results, Boston Scientific raised its full-year 2025 guidance. The company now expects adjusted EPS between $3.02 and $3.04, topping the $2.98 consensus. For the fourth quarter, it projects EPS of $0.77 to $0.79, also above the $0.76 estimate.
Boston Scientific continues to broaden its product lineup. It recently secured regulatory approval in Japan for expanded labeling of its FARAPULSE Pulsed Field Ablation System and completed the acquisition of assets from Elutia, Inc. related to antibiotic-eluting envelopes designed to prevent post-operative complications.
The company now anticipates full-year 2025 revenue growth of around 20% on a reported basis and 15.5% organically, underscoring strong momentum across its portfolio and global markets.